Ignite Creation Date:
2025-12-24 @ 10:59 PM
Ignite Modification Date:
2025-12-25 @ 8:29 PM
Study NCT ID:
NCT01621269
Status:
WITHDRAWN
Last Update Posted:
2017-04-20
First Post:
2012-04-24
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
ENGYNE Exploring Gilenya in Patients With Neutralizing Antibodies Against Interferon
Sponsor:
Novartis Pharmaceuticals
Organization:
Study Overview
Official Title:
A 12-month, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Fingolimod in the Treatment of Relapsing-remitting Multiple Sclerosis Patients With Neutralizing Antibodies to Interferon Beta
Status:
WITHDRAWN
Status Verified Date:
2014-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ENGYNE
Brief Summary:
Study to evaluate efficacy of fingolimod in patients with neutralizing antibodies over 12 months
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: